Akebia Therapeutics (AKBA)
(Delayed Data from NSDQ)
$1.34 USD
+0.01 (0.75%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.33 -0.01 (-0.75%) 5:20 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Price, Consensus and EPS Surprise
AKBA 1.34 +0.01(0.75%)
Will AKBA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AKBA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AKBA
Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4
AKBA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Rigel Pharmaceuticals (RIGL) Reports Break-Even Earnings for Q4
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
Other News for AKBA
Piper Sandler Sticks to Its Buy Rating for Akebia Therapeutics (AKBA)
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Buy Vafseo's Approval: A New Chapter For Akebia Therapeutics In Anemia Management
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)